Daily adaptive MR-guided stereotactic ablative re-irradiation (re-SABR) in oligometastatic liver disease: A single-institution retrospective analysis.

ABSTRACT:

Objective

Stereotactic ablative body radiotherapy (SABR) is an established treatment option in oligometastatic liver disease. Limited data exist on liver SABR re-irradiation (re-SABR). MR-guided SABR with daily plan adaptation and deformable image registration (DIR) allows organ-at-risk (OAR) sparing and dose accumulation in a re-irradiation setting. We report the safety and efficacy of MR-guided re-SABR in oligometastatic liver disease, alongside a DIR-based workflow for cumulative OAR dose calculation.

Methods

MR-guided re-SABR to oligometastatic liver disease was retrospectively analysed. Key inclusion criteria included: prior liver SABR, MR-guided re-SABR to ≤ 4 liver metastases, Child Pugh Score (CPS) ≤ B7, and a minimum prescribed dose of 30 Gy in 5 fractions. Lesions

SUBMITTER: Moreno-Olmedo E 

PROVIDER: S-EPMC12720006 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature